Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Ligand Binding Sites

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ID93 + GLA-3M-052-LS vaccine candidate administered by heterologous routes improves BCG efficacy against TB.

Frontiers in immunology·2026

Same author

Structure and immunological activity of QS-21 variant from <i>Quillaja saponaria</i> aerial biomass.

Frontiers in immunology·2026

Same author

Mucosal vaccination in mice provides protection from diverse respiratory threats.

Science (New York, N.Y.)·2026

Same author

The ID93 + GLA-3M-052-LS vaccine candidate elicits mucosal and systemic immunogenicity and protective efficacy against <i>Mycobacterium tuberculosis</i> challenge in BCG-primed Collaborative Cross inbred mice.

bioRxiv : the preprint server for biology·2025

Same author

Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans.

Cell·2025

Same author

A Thermostable nasal spray dried COVID vaccine candidate.

International journal of pharmaceutics·2025

Search research articles

Related Experiment Video

Updated: Mar 9, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

A structure-function approach to optimizing TLR4 ligands for human vaccines.

Darrick Carter¹, Christopher B Fox², Tracey A Day²

¹Infectious Disease Research Institute (IDRI), Seattle, WA, USA; PAI Life Sciences, Seattle, WA, USA; Department of Medicine and Global Health, University of Washington, Seattle, WA, USA.

Clinical & Translational Immunology

|December 20, 2016

Summary

This summary is machine-generated.

Researchers designed a novel adjuvant, SLA, by modifying a synthetic lipid A molecule. This new adjuvant stimulates toll-like receptor 4 (TLR4) to enhance vaccine immune responses, showing promise for safer and more effective human vaccines.

More Related Videos

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

Related Experiment Videos

Last Updated: Mar 9, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

Area of Science:

Vaccinology
Immunology
Structural Biology

Background:

Adjuvants enhance vaccine immunogenicity, historically using undefined components.
Toll-like receptor (TLR) ligands represent a new generation of adjuvants, with TLR4 ligands being prominent in human vaccines.
Understanding TLR4 ligand interactions guides the design of novel adjuvants.

Purpose of the Study:

To design and characterize a novel TLR4 ligand adjuvant with improved properties.
To evaluate the adjuvant effects of the designed molecule (SLA) in preclinical and clinical settings.
To demonstrate structure-based design for predictable adjuvant formulation.

Main Methods:

Subtle chemical modifications of a synthetic monophosphoryl lipid A molecule to create SLA.
Stimulation of human TLR4 and analysis of induced cytokines and chemokines.
Formulation of SLA in an oil-in-water emulsion and testing with a recombinant *Leishmania* vaccine antigen in mice and humans.

Main Results:

SLA demonstrated potent TLR4 stimulation with a distinct cytokine profile and lower effective concentration compared to a lipid A comparator.
SLA formulated in an emulsion elicited potent Th1-biased adaptive immune responses.
Preclinical findings in mice were recapitulated in a human clinical study, validating SLA's efficacy.

Conclusions:

Structure-based design can predictably yield modern adjuvant formulations.
SLA represents a promising designer TLR4 ligand adjuvant with potential for superior performance.
The developed adjuvant formulation is safe and effective for human vaccines.